Skip to search formSkip to main contentSkip to account menu

neratinib

An orally available, 6,7-disubstituted-4-anilinoquinoline-3-carbonitrile irreversible inhibitor of the HER-2 receptor tyrosine kinase with potential… 
National Institutes of Health

Related topics

Related topics

3 relations
HKI 272NCIt Antineoplastic Agent TerminologyReceptor Tyrosine Kinase Inhibition

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Abstract P1-13-03: Effects of neratinib after trastuzumab-based adjuvant therapy in hormone receptor-positive HER2+ early-stage breast cancer: Exploratory analyses from the phase III ExteNET trial
Background: The international, randomized, placebo-controlled phase III ExteNET trial showed that a 1-year course of neratinib… 
2018
2018
Abstract P5-21-17: Efficacy, safety and tolerability of neratinib-based therapy in patients from Asia with metastatic HER2+ breast cancer and other solid tumors: A pooled analysis of 6 clinical…
Background: HER2 overexpression/amplification occurs in ˜15–20% of primary breast cancers (BC) in western populations, although… 
2018
2018
Abstract PD3-18: The NSABP/NRG 8-gene signature accurately predicts degree of benefit from trastuzumab in Alliance/NCCTG N9831: Validation of the 8-gene signature in an independent clinical trial
BACKGROUND Clinical trials NRG/NSABP B-31 and Alliance/NCCTG N9831 demonstrated that trastuzumab added to chemotherapy extended… 
2017
2017
Neratinib Approved for HER2+ Breast Cancer.
The FDA approved the tyrosine kinase inhibitor neratinib for extended adjuvant treatment of early-stage HER2-positive breast… 
2017
2017
Abstract P2-11-03: Incidence and severity of diarrhea with neratinib + intensive loperamide prophylaxis in patients (pts) with HER2+ early-stage breast cancer (EBC): Interim analysis from the…
Background: Neratinib (Puma Biotechnology Inc) is an irreversible pan-HER inhibitor in late-phase development for the treatment… 
2017
2017
Profiling Differential Responses to Pan-HER Inhibition.
Findings from the phase II SUMMIT basket trial indicate that among patients with solid cancers harboring HER2/3 mutations… 
2016
2016
Quantitative analysis of HER family proteins using mass spectrometry as a predictive tool of response to anti-HER therapies in breast cancer
Introduccion: La expresion desregulada y la actividad de los miembros de la familia HER es frecuente en el cancer de mama (CM… 
2012
2012
Role of HER2 signaling pathway in breast cancer: biology, detection and therapeutical implications
Human epidermal growth factor receptor 2 (HER2), a member of the ErbB family of transmembrane receptor tyrosine kinases, is… 
2012
2012
Abstract OT1-1-11: TBCRC 022: Phase II Trial of Neratinib for Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast cancer and Brain Metastases
Background: 1/3 of women with metastatic HER2+ breast cancer will develop central nervous system (CNS) metastases yet evidence… 
2010
2010
Abstract P3-14-05: Safety and Efficacy of Neratinib (HKI-272) Plus Vinorelbine in the Treatment of Patients with ErbB2+ Metastatic Breast Cancer Pretreated with Anti-HER2 Therapy
Background: Neratinib (HKI-272) is an irreversible pan-ErbB tyrosine kinase inhibitor that blocks downstream signaling of the…